Effect of Topotecan on Serum CA-125 in Patients with Advanced Epithelial Ovarian Cancer
- 30 June 2000
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 77 (3) , 383-388
- https://doi.org/10.1006/gyno.2000.5760
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian CancerGynecologic Oncology, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?Cancer, 1996
- The Clinical Value of Tumour Markers in the Management of Ovarian CancerAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1996
- Tumor markers in the management of patients with ovarian cancerCancer Treatment Reviews, 1995
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- CA 125 half-life in ovarian cancer: a multivariate survival analysisBritish Journal of Cancer, 1993
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complexBiochemistry, 1989